Keytruda PopPK Simulator
Indication: Cancer immunotherapy
Population pharmacokinetic simulator for pembrolizumab (Keytruda), a humanized IgG4 monoclonal antibody targeting PD-1 (programmed cell death protein 1). Used in cancer immunotherapy across multiple solid tumors and hematologic malignancies including melanoma, NSCLC, and Hodgkin lymphoma. Simulates IV infusion PK with population variability.
Drug Overview
Clinical Context
- Molecular Target
- PD-1 (programmed cell death protein 1)
- Drug Class
- PD-1 inhibitor
- Therapeutic Area
- Oncology
- Indication
- Cancer immunotherapy
- Route of Administration
- IV
Model Information
- Model Type
- popPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pembrolizumab Pharmacokinetic Parameters
Population PK Parameters
| Parameter | Value | Description |
|---|---|---|
| Clearance (CL) | 195 - 252 mL/day | Typical population clearance range |
| Half-life (t½) | 22 - 27 days | Elimination half-life |
| Volume of Distribution (Vc) | ~6 L | Central compartment volume |
FDA-Approved Dosing Regimens
| Regimen | Dose | Frequency | Route |
|---|---|---|---|
| Standard Q3W | 200 mg | Every 3 weeks | IV infusion |
| Extended Q6W | 400 mg | Every 6 weeks | IV infusion |
📊 Q3W vs Q6W Dosing Comparison
Both regimens provide equivalent steady-state exposure (AUC) and maintain therapeutic pembrolizumab concentrations throughout the dosing interval.
200 mg Q3W (Standard)
- More frequent dosing
- Lower peak concentrations
- Narrower fluctuation range
400 mg Q6W (Extended)
- Reduced infusion visits (50% fewer)
- Higher peak concentrations
- Equivalent AUC and efficacy
Parameters sourced from FDA label and published population pharmacokinetic models. Individual patient parameters may vary based on body weight, tumor burden, and baseline characteristics.
About This Simulator
This interactive pharmacokinetic simulator for Keytruda allows you to explore concentration-time profiles under different dosing scenarios. The underlying popPK model characterizes the pharmacokinetics of this pd-1 inhibitor following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the clearance of pembrolizumab?
The clearance (CL) of pembrolizumab ranges from approximately 195 to 252 mL/day in typical patients. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of steady-state concentrations. Pembrolizumab exhibits target-mediated drug disposition, where clearance can vary based on tumor burden and patient characteristics.
What is the half-life of pembrolizumab?
Pembrolizumab (Keytruda) has an elimination half-life of approximately 22 to 27 days. This long half-life supports the approved dosing regimens of 200 mg every 3 weeks (Q3W) or 400 mg every 6 weeks (Q6W), which maintain therapeutic concentrations between doses.
What are the approved dosing regimens for Keytruda?
Keytruda (pembrolizumab) is FDA-approved for two flat dosing regimens: 200 mg administered intravenously every 3 weeks (Q3W), or 400 mg administered intravenously every 6 weeks (Q6W). Both regimens provide equivalent steady-state exposure and are not based on body weight due to the flat dose-exposure relationship observed in clinical trials.
How do Q3W and Q6W dosing regimens compare?
The 200 mg Q3W and 400 mg Q6W regimens are pharmacokinetically equivalent, providing similar average steady-state concentrations and exposure (AUC). The Q6W regimen offers increased convenience for patients by reducing infusion visits while maintaining therapeutic efficacy and safety profiles comparable to the Q3W regimen.
What is the Keytruda PK simulator?
This is a free, interactive pharmacokinetic simulator for Keytruda used in Cancer immunotherapy. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Keytruda belong to?
Keytruda is classified as a PD-1 inhibitor that targets PD-1 (programmed cell death protein 1). It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Keytruda. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a popPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Explore Other Pembrolizumab (Keytruda) Simulators
We offer multiple pembrolizumab PK simulators based on different published population pharmacokinetic models. Compare results across these implementations:
💡 Keytruda dosing calculator: Both simulators support the FDA-approved flat dosing regimens (200 mg Q3W and 400 mg Q6W) for pembrolizumab across multiple oncology indications.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the Keytruda simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community